[L-dopa with inhibitor in the treatment of parkinsonian syndrome-results of long-term observations].
The report is based on the observation of 39 patients with parkinsonian syndromes treated with L-DOPA with inhibitor, including 30 patients treated during 2-6 years. It was found that treatment with L-DOPA with the inhibitor gave good or very good results in most patients with these syndromes with a relatively good drug tolerance during the first three months. With passing time the effect of the drug on the manifestations of the disease decreases and the tolerance becomes aver worse. The results of the treatment are  worse although the applied daily dose is increased by a metan value of 50%. AT the same time  the frequency of such complications as hyperkineses, anxiety and depression labyrinthine-cerebellar signs increases. Urinary passage disturbances and mental degradation develop and their temporal association with L-DOPA treatment is unquestionable, while a cause-and-effect correlation seems likely. In the conclusion the author suggests the need for a careful consideration of each decision of treatment with L-DOPA, and the possibility of improving the results of parkinsonism treatment is seen in the production of new optimal forms of he already present drugs, monitoring blood drug levels, and practical utilization of the synergism between the group of drugs stimulating the dopaminergic system and the group of drugs inhibiting the acetylcholinergic system.
D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage*; D002230:Carbidopa / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D004338:Drug Combinations / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage* / Q000037:antagonists & inhibitors / Q000633:toxicity; D008297:Male; D008875:Middle Aged; D010302:Parkinson Disease, Secondary / Q000188:drug therapy*; D013997:Time Factors
D000978:Antiparkinson Agents; D004338:Drug Combinations; C009265:carbidopa, levodopa drug combination; D007980:Levodopa; D002230:Carbidopa
L-dopa z inhibitorem w leczeniu zespołów parkinsonowskich-wyniki dłlugotrwałej obserwacji.